Table 3.

Odds Ratio of mortality of ECMO patients with fungal infections, as compared to patients on ECMO with no fungal infection. Age group data are divided by ECMO support type sub-group. Significant increases in mortality as compared to no infection are indicated in bold typeset. Four distinct infection categories exist; no infection, infection acquired during ECMO (on-ECMO), previous fungal infection cleared during ECMO (pre-ECMO) and persistent infection throughout ECMO (all-ECMO). OR = Odds Ratio

Neonates	Acquired		Cleared		Persistent
	N	OR (95% CI)	N	OR (95% CI)	N	OR (95% CI)
All Neonates	86/118	4.77 (3.18–7.17)	20/34	2.51 (1.26–4.97)	3/5	2.63 (0.44–15.72)
VA Support	79/102	4.54 (2.85–7.24)	18/29	2.14 (1.01–4.53)	3/3
VV Support	7/16	3.97 (1.47–10.7)	2/5	3.38 (0.56–20.27)	0/2
Pediatrics		Acquired		Cleared		Persistent
	N	OR (95% CI)	N	OR (95% CI)	N	OR (95% CI)
All Pediatrics	100/173	1.59 (1.17–2.15)	39/58	2.36 (1.36–4.10)	10/13	3.82 (1.05–13.88)
VA Support	78/131	1.49 (1.05–2.12)	28/44	1.76 (0.95–3.27)	8/11
VV Support	22/42	2.51 (1.35–4.66)	11/14	8.27 (2.29–29.84)	2/2
Adults		Acquired		Cleared		Persistent
	N	OR (95% CI)	N	OR (95% CI)	N	OR (95% CI)
All Adults	50/106	0.72 (0.49–1.06)	26/33	3.09 (1.33–7.14)	3/4	2.46 (0.26–23.67)
VA Support	34/59	0.73 (0.43–1.24)	18/19	10.03 (1.33–75.37)	3/3
VV Support	16/47	0.77 (0.41–1.42)	8/14	2.03 (0.7–5.92)	0/1